Therefore, we postulate that mutations in the DNA-binding domain of STAT3 or the novel downstream genes that are upregulated by the mutant STAT3 are potential biomarkers for colon cancer diagnosis. This evidence concerns the gene STAT3 and malignant colon neoplasm.